Financial research analysts tracking Ocugen, Inc. (NASDAQ: OCGN) maintain varying twelve-month forward-looking price estimates, with consensus figures typically averaging around $10.25 per share. Projections submitted by major Wall Street institutions feature high estimates reaching up to $12.00 and lower forecasts around $8.00. Because Ocugen operates as a clinical-stage biopharmaceutical enterprise focused on breakthrough gene therapies and modifier gene platforms, these ambitious target valuations reflect potential multi-fold upside if its late-stage ophthalmic pipeline candidates successfully achieve commercialization and regulatory milestones.